Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eton Pharmaceuticals reports robust Q4 earnings, eyes accelerated growth

Eton Pharmaceuticals reported strong financial performance in Q4 2022, with a focus on accelerating growth, expanding product portfolio, and doubling sales and royalty revenue in 2023. The strategic transition to an in-house sales force for key products reflects proactive sales strategy control and market expansion efforts. While facing challenges in managing increased R&D expenses, Eton is well-positioned to capitalize on growth opportunities and achieve its long-term goal of commercializing rare disease products.

Eton Pharmaceuticals Reports Record Sales in Q1 2023, Eyes Growth

Eton Pharmaceuticals delivered impressive Q1 results with record sales and revenue growth, driven by successful product launches and strategic marketing initiatives. While facing challenges in managing expenses and legal matters, the company remains optimistic about its growth prospects and product development plans.

Eton Pharmaceuticals excels in Q2, eyes rare disease expansion

Eton Pharmaceuticals demonstrated strong financial performance and strategic growth initiatives in Q2 2023.
While facing regulatory challenges and timeline risks, the company's focus on rare diseases and acquisitions positions it for future growth.
With a solid cash position, successful product launches, and revenue projections, Eton is poised for continued success and value creation.
Navigating challenges and capitalizing on opportunities will be crucial for Eton to sustain its growth trajectory and maximize shareholder value.

Eton Pharmaceuticals excels in Q3, eyes rare disease market growth

Eton Pharmaceuticals demonstrated strong financial performance in Q3 2023, driven by revenue growth and operational efficiency.
While facing challenges in expense management and short-term profitability, the company remains focused on expanding its product portfolio and market presence.
With a solid cash position, strategic acquisitions, and a clear growth strategy, Eton is poised for continued success and revenue expansion in the coming quarters.

Eton Pharmaceuticals excels in Q4, eyes positive net income in 2024

Eton Pharmaceuticals delivered strong financial performance in Q4 2023, with revenue growth, positive cash flow, and a path to positive GAAP net income in 2024. The company's well-capitalized position, promising pipeline, and strategic growth initiatives position it for continued success. However, managing increasing operating expenses and ensuring the accretive nature of future acquisitions are key challenges.

Eton Pharmaceuticals reports robust Q1 revenue growth and strategic expansions

Eton Pharmaceuticals' Q1 performance reflects consistent revenue growth and strategic advancements.
While facing competition and M&A caution, the company is poised for growth with new products.
Opportunities lie in upcoming NDA approvals, product developments, and maintaining financial discipline.
Overall, Eton's prudent financial management and growth strategies position it for future success.

Eton Pharmaceuticals reports record Q3 earnings, eyes transformative acquisition

Eton Pharmaceuticals delivered strong financial performance in Q3 2024, with robust revenue growth, positive net income, and a strategic acquisition on the horizon. While facing challenges in sales force realignment and increased expenses, the company is poised to capitalize on opportunities with Increlex and ET-400.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12, 2022. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition.

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of Exela Pharma Sciences' Elcys™. Eton was granted 180 days of generic exclusivity as a result of being the first ANDA submitted against the reference product. The 180-day exclusivity period will begin upon Eton's commercialization of the product.

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2021 Results - Earnings Call Transcript

DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter ended December 31, 2021.

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

DEER PARK, Ill., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

Cocrystal Pharma

CTI BioPharma

ObsEva

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks to Watch With New Catalysts

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q3 2021 Results - Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -71.43% and -74.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Misses Revenue Estimates

DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021.

Eton Pharmaceuticals Reports Third Quarter Financial Results

- Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists - - Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -

Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®

The first and only FDA-approved ready-to-use liquid topiramate The first and only FDA-approved ready-to-use liquid topiramate

Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

DEER PARK, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on Monday, November 15, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

-Product is the first generic alternative to one of the highest priced pharmaceutical products in the world -Product is the first generic alternative to one of the highest priced pharmaceutical products in the world

Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2021 Results - Earnings Call Transcript

DEER PARK, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021.

Eton Pharmaceuticals Reports Second Quarter Financial Results

According to an SEC filing, the FDA action date for Eton Pharmaceuticals Inc's (NASDAQ: ETON) antiepileptic topiramate oral solution has been delayed three months to November 6. An FDA decision was expected on Friday.

Why Is Eton Pharmaceuticals (ETON) Stock Plunging On Monday?

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Eton Pharmaceuticals Inc (NASDAQ: ETON) has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector. The product is under development as a rescue treatment for adrenal crisis.

Eton Pharmaceuticals Buys US, Canadian Rights To Zeneo Hydrocortisone Autoinjector

CROSSJECT : US & Canada licensing agreement with Eton Pharmaceuticals for Crossject's ZENEO® Hydrocortisone

DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

The FDA has approved Eton Pharmaceuticals Inc's (NASDAQ: ETON) Rezipres (ephedrine hydrochloride injection) to treat clinically significant hypotension occurring in the setting of anesthesia. Rezipres is already available in Europe.

Eton Pharma Stock Is Trading Higher After FDA Approval For Rezipres

DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

Eton Pharmaceuticals, Inc. (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Eton Pharmaceuticals Inc Stock (ETON)